SAN FRANCISCO (
) -- Welcome to the J.P. Morgan Biotech Confab Live Chat.
I'm here to offer my take on the first day of the biotech sector's largest and most important investor conference. And of course, I'm happy to answer your biotech stock investing questions.
This year's J.P. Morgan conference should be renamed the Hepatitis C Hoedown for the buzz being generated about
$2.5 billion acquisition of
and the resulting speculative mania that is gripping
. Both stocks are seen as potential takeover targets, too, but how likely is that or is it just wishful thinking?
I spent my day listening to presentations by
(CELG - Get Report)
(VVUS - Get Report)
--Written by Adam Feuerstein in San Francisco.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on